Biomarkers for severe eosinophilic asthma.
The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or...
| मुख्य लेखकों: | , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| भाषा: | English |
| प्रकाशित: |
Elsevier
2017
|
| _version_ | 1826286586639155200 |
|---|---|
| author | Yancey, S Keene, O Albers, F Ortega, H Bates, S Bleecker, E Pavord, I |
| author_facet | Yancey, S Keene, O Albers, F Ortega, H Bates, S Bleecker, E Pavord, I |
| author_sort | Yancey, S |
| collection | OXFORD |
| description | The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/μL or greater or a historical blood eosinophil threshold of 300 cells/μL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment. |
| first_indexed | 2024-03-07T01:45:56Z |
| format | Journal article |
| id | oxford-uuid:9868a627-47b0-42a7-bc5e-5d17daa86b2e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:45:56Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:9868a627-47b0-42a7-bc5e-5d17daa86b2e2022-03-27T00:06:47ZBiomarkers for severe eosinophilic asthma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9868a627-47b0-42a7-bc5e-5d17daa86b2eEnglishSymplectic Elements at OxfordElsevier2017Yancey, SKeene, OAlbers, FOrtega, HBates, SBleecker, EPavord, IThe last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/μL or greater or a historical blood eosinophil threshold of 300 cells/μL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment. |
| spellingShingle | Yancey, S Keene, O Albers, F Ortega, H Bates, S Bleecker, E Pavord, I Biomarkers for severe eosinophilic asthma. |
| title | Biomarkers for severe eosinophilic asthma. |
| title_full | Biomarkers for severe eosinophilic asthma. |
| title_fullStr | Biomarkers for severe eosinophilic asthma. |
| title_full_unstemmed | Biomarkers for severe eosinophilic asthma. |
| title_short | Biomarkers for severe eosinophilic asthma. |
| title_sort | biomarkers for severe eosinophilic asthma |
| work_keys_str_mv | AT yanceys biomarkersforsevereeosinophilicasthma AT keeneo biomarkersforsevereeosinophilicasthma AT albersf biomarkersforsevereeosinophilicasthma AT ortegah biomarkersforsevereeosinophilicasthma AT batess biomarkersforsevereeosinophilicasthma AT bleeckere biomarkersforsevereeosinophilicasthma AT pavordi biomarkersforsevereeosinophilicasthma |